SanBio Signs Joint Research Agreement For Dementia Drug.
MOUNTAIN VIEW, Calif., July 23, 2018 -- SanBio Company Limited announced it has reached an agreement with Keio University School of Medicine on joint research for SB623 targeting dementia.
In development programs for proprietary regenerative cell medicine SB623, SanBio has been conducting clinical trials for chronic stroke in the U.S. and chronic traumatic brain injury in Japan and the U.S.
SB623 consists of mesenchymal stem cells derived from adult bone marrow that undergo a genetic modification.
It releases various growth factors and promotes nerve cell regeneration when administered to the injury site caused by stroke or traumatic brain injury and is considered a stem cell therapy that could bring back lost functions.
In laboratory studies that administered SB623 to the brains of stroke mice models, migration of neural stem cells to the injury site, multiplication of nerve cells, and vasculogenesis were observed.
The joint research project with Keio University aims to obtain the data required for progressing to the clinical trials stage of SB623 by evaluating the therapeutic effects of SB623 in dementia model animals.
The company will develop SB623 as a treatment for dementia, including Alzheimer's disease and cerebral vascular dementia.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Strategic Alliances|
|Publication:||Stem Cell Business News|
|Date:||Jul 23, 2018|
|Previous Article:||Positive Data Reported In PD Study In Alpha-bynuclein Worm Model.|
|Next Article:||Research Alliance To Develop Heart Failure Treatment In China.|